Physician profile
Steven E Lo
NPI 1154354074
$68,151.07
in general payments reported to CMS, 2019-2025
27 companies · $32K in 2025
The $32K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,447 · 2020: $234 · 2021: $396 · 2022: $1,301 · 2023: $18K · 2024: $15K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $7,482 · Travel and Lodging: $5,798 · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,900.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,300.00 |
| Food and Beverage | $7,482.28 |
| Travel and Lodging | $5,798.10 |
| Education | $293.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $58,736.03 | 2021-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $1,776.57 | 2019-2025 | |
| Mdd US Operations, LLC | $1,572.20 | 2019-2024 | Gocovri, Apokyn, Gocovri |
| Teva Pharmaceuticals USA, INC. | $1,412.63 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Medtronic USA, INC. | $918.23 | 2019 | |
| Merz Pharmaceuticals, LLC | $553.20 | 2022-2025 | Xeomin, Ampyra, Inbrija |
| Acadia Pharmaceuticals INC | $472.14 | 2019-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $378.45 | 2022-2025 | Crexont, Rytary, Lyvispah |
| Allergan, INC. | $367.30 | 2019-2022 | |
| Kyowa Kirin, INC. | $310.40 | 2022-2025 | Nourianz |
| Ge Healthcare | $262.56 | 2025 | |
| Adamas Pharmaceuticals, INC. | $228.82 | 2019-2021 | |
| Medtronic, INC. | $227.09 | 2024 | Percept Pc Brainsense |
| Abbott Laboratories | $198.57 | 2024-2025 | Infinity |
| Acorda Therapeutics, INC | $167.95 | 2019-2024 | Inbrija, Ampyra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $140.53 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $65.13 | 2022 | |
| Lilly USA, LLC | $58.92 | 2022-2024 | Amyvid |
| Corium, LLC | $57.94 | 2023 | Adlarity |
| Biogen, INC. | $47.82 | 2025 | Leqembi |
| Otsuka America Pharmaceutical, INC. | $44.13 | 2023 | Nuedexta |
| Avanir Pharmaceuticals, INC. | $42.10 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.15 | 2024 | |
| Revance Therapeutics, INC. | $25.10 | 2024 | Daxxify |
| Azurity Pharmaceuticals, INC. | $22.85 | 2023 | Horizant |
| Vertical Pharmaceuticals, LLC | $19.85 | 2019 | |
| Lundbeck LLC | $19.41 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.